1.Expression of vitamin D receptor in rectal carcinoma and mucosa adjacent to carcinoma
Shaohua WANG ; Weijun TANG ; Ming ZHONG
Chinese Journal of General Surgery 2000;0(11):-
Objective To evaluate the expression of vitamin D receptor (VDR) in rectal cancer and mucosa adjacent to cancer. Methods The VDR expression of tumor tissue,mucos a 2cm apart from tumor and normal mucosa was detected by imunohistochemistry, mi crospectrophotometer and computer image analysis in 21 cases of rectal carcinoma . Results The VDR expression in rec tal tumor (2.4?0.7) significantly decreased compared to that of the norma l mucosa (6.0?0.6)(P
2. Introduction and analysis to the U.S. FDA's new drug approvals in 2010
Journal of International Pharmaceutical Research 2011;38(1):71-85
In 2010, the U.S. FDA totally approved 24 new drugs, including 11 new molecular entities, 10 new biological products and 3 new vaccines. According to the prescribing information of drug specifications, this article outlines the properties, chemical name and structure, action of mechanism, manufacturer, indication, dosage and usage, contraindications, adverse reactions, boxed warning and other relevant informations of them. In addition, the "first events" in the history of new drug research and development in 2010 are also summarized, and the overview of the new drugs approval by FDA from the years of 2008 to 2010 is also analyzed.
3.Minimally Invasive Percutaneous Nephrolithotomy in the Lateral Position:Report of 48 Cases
Ming ZHONG ; Shunli TANG ; Kai LI
Chinese Journal of Minimally Invasive Surgery 2005;0(11):-
Objective To evaluate the feasibility and efficacy of minimally invasive percutaneous nephrolithotomy(MPCNL)in the lateral position.Methods A total of 48 patients with staghorn(12 cases,2.2 to 5.8 cm in diameter)or multiple renal calculi(31)or upper ureteral stones(5)were treated with MPCNL in our hospital between July 2004 to October 2007.The patients were placed in a lateral position with the head 10? lower and the feet 20? lower.The puncture was made under the guidance of X-ray or ultrasonography,and then Holmium laser or EMS lithotripter was used for stone fragmentation.The stone debris was removed by irrigation.Results The procedure was completed in all of the 48 patients except one,who was converted to a supine position because of the difficulty in puncture.Among the 47 cases,41 were cured with the first operation,the other 6 received catheterization in the first procedure,and then underwent calculi removal in a second-stage operation.None of the patients were converted to open surgery.The mean operation time in this series was(137.5?39.6)min.The one-stage cure rate in our patients was 82.9%(34/41).None of the cases had massive blood loss,or injuries to the pleura and other organs.Follow-up was available in 21 cases for 1 to 3 months.During the period,among the 17 patients who had hydronephrosis,11 were cured and 6 were improved;and among the 4 who had residual stones,1 received ESWL in 1 months after the first operation and was cured afterwards;the other 3 were treated by traditional Chinese medicine,2 of them were cured.Conclusions The MPCNL performed on the patients in the lateral position is an effective alternative for renal calculi,and favorable to intra-operative anesthesia monitor.
4.Effect and safety of primary percutaneous coronary intervention on acute ST-segment elevation myocardial infarction in elderly patients
Shenwen FU ; Xianqing HU ; Ming ZHONG ; Biao TANG ; Yanyan MAO
Chinese Journal of Geriatrics 2015;34(2):126-128
Objective To investigate the effect and safety of primary percutaneous coronary intervention (PCI) of acute ST-segment elevation myocardial infarction (STEMI) in elderly patients.Methods 103 consecutive patients with STEMI treated by primary PCI were divided into two groups according to the age:the elderly group [aged≥65 years,with a mean age of (75.7 ±6.2) years(n =49],the non-elderly group [aged<65 years,with a mean age of (43.0±8.6) years(n =54].Clinical characteristics,complications related to PCI procedure and success rate were analyzed,and major cardiovascular events (MACE) were followed up for(5.7 ± 1.2) months.Results The proportion of female,patients with Killip ≥ Ⅲ,three vessels disease and higher level of serum brain natriuretic peptide were higher in elderly group than in non-elderly group (all P<0.05).No significant difference was observed between the two groups in success rate and complications of PCI procedure (both P>0.05).Patients were followed up for (5.7± 1.2) months.The in-hospital and one-month mortalities were higher in elderly group than in non-elderly group [8.2% (4 cases)vs.0% (0 case),10.2%(5 cases) vs.0 % (0 case),respectively,all P<0.05].There was no significant difference in six-month mortality and MACE between the two groups.Multivariate logistic regression analysis showed that Killip ≥ Ⅲ was related with the increase of one-month mortality in patients with STEMI undergoing primary PCI,whereas age was not.Conclusions Primary PCI is effective and safe in elderly patients with STEMI.
5. Overviews and analysis to the U. S. FDA's new approvals in 2012
Journal of International Pharmaceutical Research 2013;40(1):111-123
In 2012, the U. S. Food and Drug Administration (FDA) approved 34 new drugs, including 23 new molecular enities and 11 new biological products. According to he prescription nformation for professionals, this article briefly describes he description, mechanism of action, the box warning, indications and usage, dosage and administration, dosage form and strength, contrandications, warning and precautions, adverse reactions, drug nteraction and use of these new drugs n special population. In addiion, the first events n he history of new drug research, development and approval are also discussed.
6. New drugs approved by the U.S. FDA (2007-2016): A review
Journal of International Pharmaceutical Research 2016;43(6):1009-1030
The introductions of the new drugs approved by the U.S. FDA have been published in the“ Journal of International Pharmaceutical Research ”for ten years. However, new problems might emerge with the increasing clinical practice and the cumulative number of patients being treated, such as the indications and purposes change, supplement of the modified efficacy, clinical data and the important new indications, constant improvement of the dosage, form and mode of administration, and the emergence of new, serious and even fatal adverse reactions urge the supplements of contraindications, warnings and precautions, or even the black box warnings. In brief, 6 entries of the introductions all may be modified, supplemented or canceled. More importantly, ten years of general analyses also find some prominent events, such as the amount of new molecular entity (NME)and new biological products come to an obvious peak in 2015. With regard to this, this paper reviewed the prominent historical events happened in the ten years in order to provide guidance and reference for new drug research and development.
7. Overviews and analysis of the U.S. FDA’ s new approvals in the first half year of 2016
Journal of International Pharmaceutical Research 2016;43(4):774-784
In the first half year of 2016, the U.S. food and drug administration (FDA) approved 9 new molecular entities and 8 new biologic license applications. According to the prescription information for professionals, this article introduces the description, mechanism of action and clinical studies; briefly describes the box warning, indications and usage, dosage and administration, dosage form and strength, contraindications, warning and precautions, adverse reactions, drug interaction and use in special population of these new drugs. In addition, the first and critical events in the history of new drug development and reaserch are emphasized.
8. Overviews and analysis of the U.S. FDA′s new approvals in the 2015 second half year
Journal of International Pharmaceutical Research 2016;43(1):167-178
In the second half year of 2015, the U.S. Food and Drug Administration(FDA)approved 20 new molecular enti-ties single or compounds and 15 biologics license applications, a total of 35 which record number of approved innovative drugs. Ac-cording to the prescription information for professionals, this article briefly describes the description, mechanism of action and clinical studies, the box warning, indications and usage, dosage and administration, dosage form and strength, contraindications, warning and precautions, adverse reactions, drug interaction and use in special population of these new drugs. In addition, the first and criti-cal events in the history of new drug development and reaserch are emphasized.
9. Overview and analysis of the U.S. FDA′s new approvals in the second half year of 2014
Journal of International Pharmaceutical Research 2015;42(1):115-126
In the second half year of 2014, the U.S. Food and Drug Administration (FDA) approved 72 new drugs, including 18 new molecular entities (NME) and 10 new biologic license application. According to the prescription information for professionals, this article introduces the description, mechanism of action and clinical studies; briefly describes the box warning, indications and usage, dosage and administration, dosage form and strength, contraindications, warning and precautions, adverse reactions, drug interaction and use in special population of these new drugs. In addition, the first and critical events in the history of new drug development and reaserch are emphasized.
10. Overviews and analysis of the U.S. FDA’s new approvals in first half year of 2015
Journal of International Pharmaceutical Research 2015;42(4):531-538
In the first half year of 2015, the U.S. Food and Drug Administration (FDA) approved 11 new molecular entities and 5 new biologic license applications. According to the prescription information for professionals, this article introduces the description, mechanism of action and clinical studies; briefly describes the box warning, indications and usage, dosage and administration, dosage form and strength, contraindications, warning and precautions, adverse reactions, drug interaction and use in special population of these new drugs. In addition, the first and critical events in the history of new drug reaserch and development are emphasized.